Plastic chemical exposure and health effects
Part of Blood & lymphatic, Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation clinical trials.
This study checks how chemicals from plastics (called plasticizers) might affect your health. Researchers will measure these chemicals in your blood or spinal fluid to see if they are linked to your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must be in one of these groups: (1) thalassemia major with regular transfusions, (2) thalassemia intermedia or minor without transfusions, (3) healthy adult, (4) brain tumor (glioma) larger than 3 cm with planned surgery that opens the brain's fluid spaces, (5) brain hemorrhage with an external drain, or (6) getting a spinal tap for diagnosis.
- You must not have any plastic implants in your body (like a plastic hip or similar).
- You must not have a chronic infectious disease and, if female, not be pregnant.
- You must not be taking certain medications, drugs, or alcohol if you are in the healthy group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
This study tests an experimental medicine called YOLT-204 for people with beta-thalassemia who need regular blood transfusions. The goal is to see if this treatment is safe and if it might reduce the need for transfusions.
This trial tests a new treatment called KL003 for people with beta-thalassemia who need regular blood transfusions. The treatment uses your own stem cells (collected from your blood) to try to reduce or stop the need for transfusions.
This study looks at how children with transfusion-dependent beta-thalassemia grow and develop after gene therapy. It compares children who have had gene therapy with those who have not, and also with healthy children of the same age and gender.
This trial tests a new drug, 9MW3011, in people with a type of beta-thalassemia that does not require regular blood transfusions. The goal is to see if the drug can safely help manage iron overload and improve hemoglobin levels.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.